Collaboration will focus on combining BIND's technology with Roche's proprietary therapeutic payloads and targeting ligands
BIND Therapeutics, a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins, has entered into a research agreement with Roche to discover novel nanomedicines using Accurins for the treatment of diseases in therapeutic areas outside oncology. The collaboration will focus on combining BIND's technology with Roche's proprietary therapeutic payloads and targeting ligands.
'The addition of Roche, a global leader and innovator, to our family of collaborators underscores BIND's unique, leading position in the field of nanomedicine,' said Scott Minick, Chief Executive Officer of BIND Therapeutics. 'By combining BIND's Medicinal Nanoengineering platform with Roche's deep expertise in disease areas with high unmet medical need, this agreement further validates the wide-ranging potential for our technology and facilitates extending our platform into new therapeutic areas.'
BIND Therapeutics intends to leverage its Medicinal Nanoengineering platform to develop a pipeline of Accurins, initially in oncology, as well as Accurins in collaboration with biopharmaceutical companies. The company's lead drug candidate, BIND-014, is an Accurin that targets PSMA and contains docetaxel. BIND-014 is currently in Phase 2 clinical trials for non-small cell lung cancer and metastatic castrate-resistant prostate cancer.
BIND has announced collaborations with Amgen , Pfizer and AstraZeneca to develop Accurins based on therapeutic payloads from their product pipelines. BIND's platform originated from the pioneering nanotechnology research at the Massachusetts Institute of Technology and Brigham and Women's Hospital/Harvard Medical School of BIND's scientificfounders and directors Dr Robert Langer and Dr Omid Farokhzad.